14 biotech podcasts to tune into in 2026

The biotech and pharmaceutical industries are increasingly utilizing podcasts as a vital tool for professionals to keep pace with rapid technological advancements and market shifts. These audio programs provide a platform for experts to discuss clinical trials, emerging therapies, and strategic dealmaking within the healthcare sector. By featuring insights from CEOs and investors, these podcasts serve as an essential resource for navigating the complex biopharma landscape of 2026.

The "Beyond Biotech" podcast, hosted by Labiotech’s Dylan Kissane, leads the 2026 list by providing weekly insights from biopharma experts on clinical trials and emerging trends. Recent episodes have featured Hakan Goker of M Ventures discussing the recent surge in mergers and acquisitions (M&A) within the industry. This focus on high-level strategy is mirrored in the "Business of Biotech" podcast, where host Ben Comer interviews leaders like Zymeworks CEO Kenneth Galbraith about drug development, funding, and shifting business models such as royalty-based value creation.

Strategic growth and future technologies are also central themes in the "Biotech2050" podcast, led by Alok Tayi of Vibe Bio and Rahul Chaturvedi of Clora. A recent highlight included an interview with Roivant Sciences CEO Matt Gline, who detailed the challenges of developing treatments for autoimmune conditions like dermatomyositis and the requirements for building a lasting biotech firm. These discussions provide critical context for stakeholders monitoring the intersection of drug discovery and corporate sustainability in the current market.

For those focused on the human capital and social aspects of the industry, podcasts like "Biotech Career Coach" and "The Long Run" offer specialized content. Carina Clingman’s career-focused show provides tactical advice on networking and resume building for the 2026 job market, while Luke Timmerman’s "The Long Run" explores systemic issues such as gender and race inequality in biotech. Timmerman’s recent coverage included an interview with former Blueprint Medicines CEO Kate Haviland regarding the company’s transition from immunology to its significant $9.5 billion acquisition by Sanofi.